Del Global settles SEC dispute

Article

X-ray equipment manufacturer Del Global Technologies has obtained final approval from the Securities and Exchange Commission regarding the settlement of claims against the company in connection with the restatement of financial statements filed by former

X-ray equipment manufacturer Del Global Technologies has obtained final approval from the Securities and Exchange Commission regarding the settlement of claims against the company in connection with the restatement of financial statements filed by former management for the fiscal years 1997 through the third quarter of fiscal 2000. The terms of the settlement are subject to approval by the U.S. District Court for the Southern District of New York. Del Global signed a consent decree with the SEC in December involving payment of a civil penalty of $400,000. The company is primarily engaged in the design, manufacture, and marketing of x-ray systems for the medical and dental markets, as well as high-voltage power conversion subsystems for medical and other industrial applications.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.